LeMaitre Vascular (LMAT)
Nasdaq Market Closed
LeMaitre Vascular, Inc. is a medical technology company focused on products used by vascular surgeons and related specialists. Its devices and services support the treatment of peripheral vascular disease, cardiovascular conditions, and end-stage renal disease, including procedures involving arteries, veins, and vascular access. The company’s portfolio includes branded surgical products used in open vascular procedures, a market that is more specialised and less crowded than some broader areas of medical devices.
LeMaitre develops, manufactures, markets, and sells its products directly to hospitals and physicians in many markets. Its customer base is primarily vascular surgeons, although cardiac, general, and neurosurgeons may also use selected products. The company’s offerings are designed for procedures such as vessel repair, bypass, embolectomy, shunt placement, and access creation, depending on the product line. It also provides human tissue cryopreservation services, adding a service-based element alongside its device portfolio.
The company operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the Americas contributing the largest share of revenue. Its business model relies on a combination of established niche products, surgeon familiarity, regulatory approvals, manufacturing capability, and a specialised sales organisation. LeMaitre has historically pursued growth through product development and acquisitions of vascular product lines that fit its focused commercial channel.
For investors, LeMaitre stands out as a smaller, specialised healthcare company rather than a broad medical-device conglomerate. Demand is linked to the prevalence of vascular disease, ageing populations, surgical procedure volumes, hospital purchasing patterns, and the adoption of specific surgical techniques. Its distinctive position comes from concentrating on the practical needs of vascular surgeons with a diversified set of branded products.
Last updated
- Market Cap
- 2.09B
- P/E
- 33.55
- P/FCF
- 26.46
- P/S
- 8.17
- Enterprise Value
- 2.24B
- Sector
- Health Care
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 63 SECOND AVENUE, BURLINGTON, MA, 01803
LeMaitre to Participate at Upcoming Investor Conferences in March
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering
LeMaitre to Participate at Upcoming Investor Conferences in November
LeMaitre to Participate at Upcoming Investor Conferences in September
LeMaitre Will Announce Second Quarter 2024 Earnings Results August 1, 2024 - GlobeNewswire
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
Encompass Health (EHC) Expands in Louisville With New Rehab Unit
GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow
Encompass Health (EHC) Gains 30% in a Year: More Room to Run?
LeMaitre (LMAT) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for June 21st
Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers
My Dividend Growth Portfolio
Compelling Reasons to Hold on to Ensign Group (ENSG) Stock
Dividend Champion, Contender, And Challenger Highlights: Week Of May 26
UnitedHealth Unit (UNH) Wins Medicaid Deal to Serve Kansas
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 2.09B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 2.24B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 33.55
- P/B
P/B ratio compares a company's share price to its book value per share.
- 5.15
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 8.17
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 26.76
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 8.72
- EPS
- 2.73
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.92%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 26.46
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 23.98
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 79.12M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 15.35%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 9.91%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.42
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 14.32
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 12.2
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.8
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 267.99K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 91.62
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 66.55M | 64.45M | 61.05M | 64.23M | 59.87M |
| Gross profit | 48.4M | 46.19M | 45.96M | 44.97M | 41.42M |
| Operating income | 17.78M | 18.83M | 20.31M | 16.14M | 12.63M |
| EBITDA | 20.4M | 21.44M | 22.93M | 18.79M | 15.18M |
| Net income | 15.68M | 15.58M | 17.36M | 13.78M | 11.01M |
| Basic EPS | 0.69 | 0.69 | 0.77 | 0.61 | 0.49 |
| Diluted EPS | 0.68 | 0.68 | 0.75 | 0.6 | 0.48 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 629.53M | 615.69M | 598.07M | 577.59M | 556.01M |
| Total liabilities | 222.9M | 222.17M | 219.15M | 214.91M | 208.43M |
| Total equity | 406.62M | 393.52M | 378.92M | 362.69M | 347.57M |
| Cash & equivalents | 26.85M | 28.24M | 25.49M | 27.18M | 25.34M |
| Current assets | 477.82M | 468.23M | 452.03M | 430.13M | 408.11M |
| Current liabilities | 33.37M | 36.32M | 33.29M | 30.82M | 24.75M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 15.09M | 23.16M | 28.76M | 20.29M | 9.04M |
| Investing cash flow | -13.12M | -16.83M | -27.45M | -16.35M | -4.32M |
| Financing cash flow | -3.22M | -3.59M | -2.95M | -2.76M | -5.24M |
| Change in cash | -1.39M | 2.75M | -1.68M | 1.84M | -270K |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SD — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | SCHEDULE 13G/A — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 144 — LEMAITRE VASCULAR INC | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| edgar index | 144 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 144 — LEMAITRE VASCULAR INC | View Filing | |
| form 4 | Form 4 — Jasinski Lawrence J | View Filing | |
| form 4 | Form 4 — Jasinski Lawrence J | View Filing | |
| form 4 | Form 4 — Jasinski Lawrence J | View Filing | |
| form 4 | Form 4 — Jasinski Lawrence J | View Filing | |
| form 4 | Form 4 — Jasinski Lawrence J | View Filing | |
| form 4 | Form 4 — Jasinski Lawrence J | View Filing | |
| form 4 | Form 4 — Jasinski Lawrence J | View Filing | |
| form 4 | Form 4 — Ross Bridget A | View Filing | |
| form 4 | Form 4 — Ross Bridget A | View Filing | |
| form 4 | Form 4 — Ross Bridget A | View Filing | |
| form 4 | Form 4 — Ross Bridget A | View Filing | |
| form 4 | Form 4 — Ross Bridget A | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| edgar index | 10-Q — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 8-K — LEMAITRE VASCULAR INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| form 4 | Form 4 — Pellegrino Joseph P JR | View Filing | |
| form 4 | Form 4 — Pellegrino Joseph P JR | View Filing | |
| edgar index | ARS — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 8-K — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | DEF 14A — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | DEFA14A — LEMAITRE VASCULAR INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | 4 — LEMAITRE VASCULAR INC | View Filing | |
| edgar index | SCHEDULE 13G/A — LEMAITRE VASCULAR INC | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeMaitre George W | View Filing | |
| form 4 | Form 4 — LeBlanc Dorian Paul | View Filing | |
| form 4 | Form 4 — LeBlanc Dorian Paul | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — Kamke Trent G | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Roberts David B | View Filing | |
| form 4 | Form 4 — Pellegrino Joseph P JR | View Filing | |
| form 4 | Form 4 — Pellegrino Joseph P JR | View Filing | |
| form 4 | Form 4 — Pellegrino Joseph P JR | View Filing |